Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HS 20093

Next Previous
X
Search
Drug Profile

HS 20093

Alternative Names: GSK-5764227; HS-20093

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hansoh Biomedical
  • Developer Hansoh BioMedical R&D Company; Shanghai Hansoh Biomedical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer; Oesophageal cancer; Osteosarcoma; Prostate cancer; Sarcoma; Solid tumours

Most Recent Events

  • 20 Aug 2024 HS 20093 receives Breakthrough Therapy status for Small cell lung cancer (Second-line therapy or greater) in USA
  • 13 Aug 2024 GSK plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Argentina, Canada, France, Italy, Japan, Spain and UK in August 2024 (NCT06551142)
  • 30 Jul 2024 Hansoh BioMedical plans a phase III ARTEMIS-009 trial for Small cell lung cancer in September 2024 (IV) (NCT06526624)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top